Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of General and Pancreatic Surgery, Verona University Hospital, Verona, Italy.
Ann Surg Oncol. 2020 Oct;27(10):3939-3947. doi: 10.1245/s10434-020-08427-4. Epub 2020 Apr 7.
The incidence and magnitude of indicators of radiographic response of pancreatic cancer to systemic chemotherapy and (chemo)radiation administered prior to anticipated pancreatectomy are unclear.
Sequential computed tomography scans of 226 patients with localized pancreatic cancer who received chemotherapy consisting of 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFIRINOX) or gemcitabine and nanoparticle albumin-bound paclitaxel (GA) with or without (chemo)radiation and who subsequently underwent surgery with curative intent from January 2010 to December 2018 at The University of Texas MD Anderson Cancer Center and Verona University Hospital were re-reviewed and compared.
Overall, 141 patients (62%) received FOLFIRINOX, 70 (31%) received GA, and 15 (7%) received both; 164 patients (73%) received preoperative (chemo)radiation following chemotherapy and prior to surgery; and 151 (67%), 70 (31%), and 5 (2%) patients had Response Evaluation Criteria in Solid Tumors (RECIST) stable disease, partial response, and progressive disease, respectively. The tumors of 29% of patients with borderline resectable or locally advanced cancer were downstaged after preoperative therapy. Radiographic downstaging was more common with chemotherapy than with (chemo)radiation (24% vs. 6%; p = 0.04), and the median tumor volume loss after chemotherapy was significantly greater than that after (chemo)radiation (28% vs. 17%; p < 0.01).
Less than one-third of patients treated with FOLFIRINOX or GA with or without (chemo)radiation experienced either RECIST partial response or radiographic downstaging prior to surgery. The incidence of tumor downstaging was higher and the magnitude of tumor volume loss was greater following chemotherapy than after (chemo)radiation.
在预期行胰腺切除术之前,接受全身化疗和(放)化疗治疗的胰腺癌患者的影像学反应指标的发生率和程度尚不清楚。
对 2010 年 1 月至 2018 年 12 月期间在德克萨斯大学 MD 安德森癌症中心和维罗纳大学医院接受氟尿嘧啶、亚叶酸、奥沙利铂和伊立替康(FOLFIRINOX)或吉西他滨和纳米白蛋白结合紫杉醇(GA)化疗加或不加(放)化疗且随后行根治性手术的 226 例局限性胰腺癌患者的连续 CT 扫描进行了重新回顾和比较。
总体而言,141 例患者(62%)接受了 FOLFIRINOX,70 例患者(31%)接受了 GA,15 例患者(7%)接受了两种治疗;164 例患者(73%)在化疗后并在手术前接受了术前(放)化疗;151 例(67%)、70 例(31%)和 5 例(2%)患者的 RECIST 标准分别为疾病稳定、部分缓解和疾病进展。边界可切除或局部晚期癌症患者中有 29%的肿瘤降期。与(放)化疗相比,化疗更常见肿瘤降期(24%比 6%;p=0.04),化疗后肿瘤体积损失中位数明显大于(放)化疗后(28%比 17%;p<0.01)。
在接受 FOLFIRINOX 或 GA 化疗加或不加(放)化疗的患者中,不到三分之一的患者在手术前出现 RECIST 部分缓解或影像学降期。与(放)化疗相比,化疗后肿瘤降期发生率更高,肿瘤体积损失更大。